诺瓦瓦克斯医药周二公布第三季度收入为8450万美元,低于去年同期的1.87亿美元。
三季度摊薄后每股亏损0.76美元,较去年同期1.26美元的亏损有所收窄。
公司将2024年营业收入指引降至6.5亿至7亿美元,低于先前的指引和分析师预期;公司预计产品销售额将在1.75亿至2.25亿美元之间,低于之前的2.75亿至3.75亿美元的指引。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.